hsd1

11β-HSD1 inibitor 19 shows inhibitory activities for hHSD1 and mHSD1 with IC50s of 16 nM and 10 nM.

11β-HSD1-IN-1 is an inhibitor of 11β-hydroxydehydrogenase 1 (11β-HSD1, IC50: 52 nM) used for the treatment of pain.

11β-HSd1-in-11 is a potent and competitive inhibitor of 11-β-hydroxysteroid dehydrogenase 1 (11β-HSD1) IN rats and humans with IC50 values of 0.34 μM and 0.13 μM, respectively. 11β-Hsvd1-in-11 is a compound used as a chemical compound. 11β-HSD1-IN-11 is a hormone involved in regulating various physiological processes, such as metabolism, inflammation, and stress responses. 11β-Hd1-in-11 is a potential compound for the treatment of metabolic disorders, obesity, and certain inflammatory conditions.

11β-HSD1 inibitor 17 is an inhibitor of 11β-hydroxysteroid dehydrogenase (11β-HSD1).

11β-HSD1-IN-12 is an 11β-HSD1 inhibitor.11β-HSD1-IN-12 is implicated in the conversion of glucocorticoids in vivo and can be used to study metabolic syndrome and obesity.

17β-HSD1-IN-1 (Compound 1) is a highly selective inhibitor of 17β-HSD1 with IC50 values of 5.6 nM for 17β-HSD1 and 3155 nM for 17β-HSD2, and it can be used in non-small cell lung cancer (NSCLC) research [1].

11β-HSD1-IN-6 is a potent inhibitor of 11β hydroxysteroid dehydrogenase enzymes (11β-HSDs), which catalyze the conversion of active glucocorticoids, corticosterone or cortisol, to their inactive forms, 11-dehydrocorticosterone (11-DHC) and cortisone. The compound specifically targets and inhibits 11β-HSD-1, modulating the interconversion of these glucocorticoids. [1]

Steroid sulfatase/17β-HSD1-IN-1 is a highly effective inhibitor of steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) activities, with an IC50 value of 28 nM against cellular human steroid sulfatase. This compound holds significant potential for investigating estrogen-dependent diseases [1].

Steroid sulfatase/17β-HSD1-IN-4 (compound 37) is a potent dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). Steroid sulfatase/17β-HSD1-IN-4 irreversibly inhibits hSTS activity (IC50= 63 nM) and has research value in endometriosis and other estrogen-dependent diseases.

Steroid sulfatase/17β-HSD1-IN-3 (compound 19) is a dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 [17β-HSD1], useful in studying endometriosis and other estrogen-dependent diseases.

11β-HSD1-IN-8 is a useful organic compound for research related to life sciences. The catalog number is T65743 and the CAS number is 386704-15-0.

11β-HSD1-IN-7 is a useful organic compound for research related to life sciences. The catalog number is T67622 and the CAS number is 728-86-9.

11β-HSD1-IN-10, a potent inhibitor of 11β-HSD1 with an IC50 value of 1.8 µM for humans, is suitable for research into obesity, hyperglycemia, and cognitive impairment.

11β-HSD1-IN-9 is a potent inhibitor of 11β-HSD1, displaying IC50 values of 0.48 µM for human and 1.3 µM for murine variants, respectively. It exhibits competitive interaction with rat 11β-HSD1. This compound holds potential utility in research focused on obesity, hyperglycemia, and cognitive impairment.

Steroid sulfatase/17β-HSD1-IN-5 is an irreversible inhibitor of steroid sulfatase (STS) and a reversible, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), with IC50 values of 43 nM for 17β-HSD1 and 6.2 μM for 17β-HSD2. This compound is utilized in research related to metabolic diseases, particularly endometriosis [1].

HSD17B13 degrader 2, a PROTAC target protein ligand (Ligands for Target Protein for PROTACs), is designed for synthesis applications.

FXR HSD17B13 modulator 1 (compound 6) is an effective modulator of FXR HSD17B13, playing a significant role in studies related to metabolic dysfunction-associated steatohepatitis (MASH).

HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value for the substrate estradiol LCMS of ≤ 50 nM. It can be utilized in research on liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD, NASH, or drug-induced liver injury (DILI).

HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. It is applicable in research on liver diseases, metabolic disorders, or cardiovascular conditions, such as NAFLD or NASH, or drug-induced liver injury (DILI).

HSD17B13-IN-101 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. It is applicable in research on non-alcoholic fatty liver disease (WO2023146897A1; compound 94).

HSD1590 is a highly effective and potent inhibitor of ROCK1 and ROCK2, with IC50 values of 1.22 nM and 0.51 nM, respectively. It demonstrates exceptional binding affinity to ROCK, with Kd values below 2 nM. Moreover, HSD1590 showcases minimal cytotoxicity, making it an ideal compound for various applications.

17β-HSD10-IN-1 is an orally available 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) inhibitor with blood-brain permeability and potency for the study of Alzheimer's disease.

17β-HSD10-IN-2 (compound 11), a benzothiazolylurea-based inhibitor, specifically targets 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), avoiding mitochondrial off-targets and cytotoxic or neurotoxic effects. This multifunctional mitochondrial enzyme inhibitor has potential applications in Alzheimer's disease (AD) and hormone-dependent cancer research [1].

HSD17B13-IN-2 (compound 1) is a potent inhibitor of hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13), exhibiting demonstrable activity in cellular experiments [1].